Thank you for your participation!
Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
About the Conference
The First Stop for Growing Your
The 15th Annual Trans-Pacific Health Sciences Dialogue is a meeting for biopharmaceutical industry executives and business development executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.
This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Take a look at some photos from the 2016 Trans-Pacific Health Sciences Dialogue!
Industry News from FiercePharmaAsia
- FiercePharmaAsia—NextCODE’s $240M financing, Celltrion’s Inflectra plant, Biocon’s insulin plantWuXi NextCODE has raised $240 million in a series B to build its genomics business, FDA slapped Pfizer's partner Celltrion with a 12-observation Form 483, Biocon's $275 million insulin plant in Malaysia opened shop and more.
- FDA faults Celltrion plant that makes Pfizer's Remicade copy, InflectraPfizer is leaning heavily on Celltrion for its biosimilar development and manufacturing, but its South Korean partner has stumbled with an FDA inspection that uncovered issues at its plant in Incheon.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an event for biopharmaceutical executives, KOLs, select industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.